4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide

ID: ALA4860970

Chembl Id: CHEMBL4860970

PubChem CID: 67819604

Max Phase: Preclinical

Molecular Formula: C20H19F2N5O

Molecular Weight: 383.40

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(F)c(F)c3)ncnc12

Standard InChI:  InChI=1S/C20H19F2N5O/c21-15-6-5-12(9-16(15)22)17(10-27-7-2-8-27)26-20-14-4-1-3-13(19(23)28)18(14)24-11-25-20/h1,3-6,9,11,17H,2,7-8,10H2,(H2,23,28)(H,24,25,26)/t17-/m1/s1

Standard InChI Key:  FJZFOTKMZCYJDF-QGZVFWFLSA-N

Associated Targets(Human)

AKT1 Tchem Serine/threonine-protein kinase AKT (9192 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AURKB Tchem Aurora kinase B/Inner centromere protein (233 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 383.40Molecular Weight (Monoisotopic): 383.1558AlogP: 2.87#Rotatable Bonds: 6
Polar Surface Area: 84.14Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 7.44CX LogP: 2.32CX LogD: 2.00
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.68Np Likeness Score: -1.57

References

1. DeSelm L, Huck B, Lan R, Neagu C, Potnick J, Xiao Y, Chen X, Jones R, Richardson TE, Heasley BH, Haxell T, Moore J, Tian H, Georgi K, Rohdich F, Sutton A, Johnson T, Mochalkin I, Jackson J, Lin J, Crowley L, Machl A, Clark A, Wilker E, Sherer B, Goutopoulos A..  (2021)  Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.,  64  (19.0): [PMID:34596404] [10.1021/acs.jmedchem.1c01087]

Source